Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 30,500 shares, a decrease of 49.0% from the December 31st total of 59,800 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Maxim Group upgraded Talphera to a “strong-buy” rating in a research note on Friday, November 8th. Rodman & Renshaw initiated coverage on Talphera in a research note on Tuesday. They set a “buy” rating and a $4.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Talphera in a report on Tuesday, January 21st. Finally, RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a report on Tuesday.

Talphera Stock Performance

Shares of NASDAQ TLPH traded down $0.03 during mid-day trading on Wednesday, reaching $0.70. The company’s stock had a trading volume of 35,141 shares, compared to its average volume of 101,124. The stock has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.81. The stock has a market capitalization of $11.94 million, a P/E ratio of -1.02 and a beta of 0.28. Talphera has a 1-year low of $0.50 and a 1-year high of $1.61.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th biggest position. Rosalind Advisors Inc. owned about 4.47% of Talphera as of its most recent SEC filing. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.